D. Li et al., Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: Cytochrome P450 oxidoreductase in bladder tissues and tumors, J UROL, 166(6), 2001, pp. 2500-2505
Purpose: We previously showed that mitomycin C activity in human bladder tu
mors is inversely related to tumor stage and muscle invasive tumors are les
s sensitive than superficial tumors. Because DT-diaphorase and reduced nico
tinamide adenine dinucleotide phosphate: cytochrome P450 oxidoreductase (P4
50R) have a role in mitomycin C bioactivation, we investigated the distribu
tion of these enzymes as a function of depth in the bladder wall and in hum
an bladder tumors located at different parts of the bladder.
Materials and Methods: Gene expression of DT-diaphorase and P450R relative
to the expression of beta -actin was measured by reverse transcriptase-poly
merase chain reaction in 4 dog and 8 human bladder tissue specimens, and in
46 human bladder tumors. DT-diaphorase activity was measured by enzymatic
assay in dog and human bladders.
Results: Data showed decreasing expression of DT-diaphorase and P450R from
urothelium to muscle layer in the normal bladder wall with higher interindi
vidual variation in humans than in dogs (greater than 40-fold versus approx
imately 3-fold). The expression of DT-diaphorase and P450R in bladder tumor
s correlated inversely with tumor stage (p < 0.05) and was significantly hi
gher in superficial than in muscle invasive bladder disease. DT-diaphorase
and P450R expression in bladder tumors was approximately 6-fold higher than
in normal bladder tissue. In normal and tumor tissues DT-diaphorase expres
sion correlated significantly with P450R (r(2) = 0.33, p <0.01), while DT-d
iaphorase expression correlated with its enzyme activity (r(2) = 0.84, p <
0.01).
Conclusions: Our results indicate a higher distribution of DT-diaphorase an
d P450R in superficial bladder tumors and tissues. Preferential enzyme dist
ribution in superficial tumors may be a cause of the higher efficacy of int
ravesical mitomycin C therapy for superficial versus muscle invasive diseas
e.